Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
99.9%Free Cash Flow to Operating Cash Flow
VS
Market
Sector
Industry
History
$ 14.26Close
$ 8.21 - $ 14.6 52-Week Range
Ticker Information
Ticker
TBPHCompany Name
THERAVANCE BIOPHARMA INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTHERAVANCE BIOPHARMA INC - Free Cash Flow to Operating Cash Flow Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
TBPH - FCF/OCF Historical data
| Date | Free Cash Flow | Free Cash Flow to Operating Cash Flow | Net Cash Flow - Operations |
|---|---|---|---|
| 6/30/2025 | $ 244.78M | 99.9% | $ 245.01M |
| 3/31/2025 | $ 32.28M | 99.26% | $ 32.53M |
| 12/31/2024 | $ -11.87M | 0% | $ -11.54M |
| 9/30/2024 | $ -12.31M | 0% | $ -11.49M |
| 6/30/2024 | $ -9.6M | 0% | $ -8.78M |
| 3/31/2024 | $ -17.14M | 0% | $ -16.8M |
| 12/31/2023 | $ -27.97M | 0% | $ -27M |
| 9/30/2023 | $ -150.76M | 0% | $ -150.2M |
| 6/30/2023 | $ -170.34M | 0% | $ -169.85M |
| 3/31/2023 | $ -173.18M | 0% | $ -172.14M |
Key Performance Insights, Last 5 Years
- THERAVANCE BIOPHARMA INC's latest trailing twelve months (TTM) FCF/OCF stands at 0%.
- Over the past 5 years, THERAVANCE BIOPHARMA INC's average FCF/OCF has been 99.58%.
- The median FCF/OCF for THERAVANCE BIOPHARMA INC during this period was 99.58%
- THERAVANCE BIOPHARMA INC reached its highest FCF/OCF over the past 5 years at 99.9%.
- The lowest FCF/OCF recorded by THERAVANCE BIOPHARMA INC in the same timeframe 99.26%
THERAVANCE BIOPHARMA INC's FCF/OCF vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
FCF/OCF Benchmarks
Similar metrics to CF - Operations:
- Price to Operating Cash Flow - [Calculation] Measures a company’s [MarketCap] in relation to its Operating Cash Flow [NCFO].
- Capital Expenditures to Operating Cash Flow - [Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
- Operating Cash Flow Margin - [Calculation] The company's operating cash flow [NCFO] expressed as a percentage of [Revenue].
- Net Cash Flow - Operations - [Cash Flow Statement] Cash flow from operations represents the amount of cash inflow (outflow) that a company generates (consumes) from operating activities. Similar to Net Income [NetIncCmn] but harder to manipulate and ignoring effects of non-cash charges like depreciation.
- Operating Cash Flow per Share - [Calculation] The amount of Operating Cash Flow attributed to each share, calculated as [NCFO] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
Definition of Free Cash Flow to Operating Cash Flow
[Calculation] The Free Cash Flow to Cash Flow from Operations ratio, describes how much of a company’s operating cash flow [NCFO] is free to be invested after capital expenditures [CapEx].FCF / CF - Operations
(=) FCF/OCF FCF/OCF for THERAVANCE BIOPHARMA INC is calculated as follows: FCF [ $ -256.47M ] / CF - Operations [ $ -249.83M ]
(=) FCF/OCF [ 0% ] TBPH - Free Cash Flow to Operating Cash Flow, Last 5 years
99.26%
Minimum
Mar 31, 2025
99.9%
Maximum
Jun 30, 2025
99.58%
Average
99.58%
Median
FCF/OCF Benchmark AnalysisMarket
The chart above depicts the distribution of FCF/OCF for companies in the Total Stock Market. The average FCF/OCF of the companies is 71.44% with a standard deviation of 29.12%.
The following table provides additional summary stats:
FCF/OCF in the Market:
| filtered constituents | 2.51K |
|---|---|
| min | -23% |
| max | 171.58% |
| average | 71.44% |
| median | 80.83% |
| std | 29.12% |